PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M upon the closing of the transaction. PTC was granted the ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint: Warren, New Jersey Thursday, November 28, 2024, 15:00 Hrs [IST] PTC The ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...

In a report released on November 25, Brian Abrahams from RBC Capital maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $39.00. The company’s shares closed ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention that ...

Are the performing arts part of your Utah holiday traditions? Here's where you can see Ballet West's "The Nutcracker," hear ...

With freezing temperatures settling across the UK, people are looking at cheaper ways to warm their homes for less ...

Donald Trump said during his presidential campaign that he wants to make the Affordable Care Act "much better for far less ...

The U.S. Food and Drug Administration has approved Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and ...